Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade F 0.969 -3.09% -0.03
ADAP closed down 3.09 percent on Friday, October 18, 2019, on 3.35 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADAP trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Reversal New Lows Setup Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
New 52 Week Low Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -3.09%
Outside Day Range Expansion -3.09%

Older signals for ADAP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Cancer Immunotherapy Non Small Cell Lung Cancer Virotherapy Ovarian Cancer Multiple Myeloma Melanoma Oncolytics Biotech Adoptive Cell Transfer Hematological Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Products Esophageal Cancer Breast And Lung Cancer
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.11
52 Week Low 0.95
Average Volume 321,407
200-Day Moving Average 3.4762
50-Day Moving Average 1.511
20-Day Moving Average 1.2559
10-Day Moving Average 1.0339
Average True Range 0.1382
ADX 34.51
+DI 11.5641
-DI 26.0011
Chandelier Exit (Long, 3 ATRs ) 1.3654
Chandelier Exit (Short, 3 ATRs ) 1.3646
Upper Bollinger Band 1.7466
Lower Bollinger Band 0.7652
Percent B (%b) 0.21
BandWidth 78.143164
MACD Line -0.2043
MACD Signal Line -0.1977
MACD Histogram -0.0065
Fundamentals Value
Market Cap 90.62 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -0.98
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.19
Resistance 3 (R3) 1.21 1.16 1.16
Resistance 2 (R2) 1.16 1.10 1.15 1.14
Resistance 1 (R1) 1.06 1.06 1.03 1.04 1.13
Pivot Point 1.01 1.01 0.99 1.00 1.01
Support 1 (S1) 0.91 0.95 0.88 0.89 0.81
Support 2 (S2) 0.86 0.91 0.85 0.79
Support 3 (S3) 0.76 0.86 0.78
Support 4 (S4) 0.74